Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Clinical Trials Using Apalutamide

Review the clinical trials studying apalutamide on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-21 of 21

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy after Surgery for Prostate Cancer, INNOVATE Trial
Status: Active
Location: 332 locations
Treating Prostate Cancer That Has Come Back after Surgery with Apalutamide and Targeted Radiation Based on PET Imaging, INDICATE Trial
Status: Active
Location: 305 locations
Docetaxel and Hormone Treatment Compared to Hormone Treatment Alone in People with Metastatic Castration Sensitive Prostate Cancer and Less than Optimal PSA Response, TRIPLE-SWITCH Trial
Status: Active
Location: 238 locations
2141-V11 in Combination with Standard Therapy for the Treatment of Prostate Cancer Prior to Surgery
Status: Active
Location: 7 locations
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer
Status: Active
Location: 8 locations
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Status: Active
Location: 7 locations
Apalutamide and Carotuximab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Status: Active
Location: 3 locations
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Status: Active
Location: 6 locations
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for the Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
Status: Active
Location: 3 locations
A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Status: Active
Location: 3 locations
Androgen Ablation Therapy with or without Niraparib after Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
Status: Active
Location: 2 locations
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
Status: Active
Location: 2 locations
A Study of Personalized Apalutamide Treatment for Improving Quality of Life in Patients with Prostate Cancer after Post Operative Radiation, PROSTATE-IQ Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
Status: Active
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients with Prostate Cancer, HEATWAVE Trial
Status: Active
Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California
Adaptive Androgen Deprivation Therapy and Docetaxel for the Treatment of Metastatic Castration Sensitive Prostate Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Metastasis-Directed Radiotherapy for the Treatment of Men with Oligometastatic Prostate Cancer, METANOVA Trial
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Sipuleucel-T with or without Continuing New Hormonal Agents (NHA) for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer with PSA Progression while on NHA and LHRH Analog
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Status: Active
Location: See ClinicalTrials.gov
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants with Metastatic Castration Resistant Prostate Cancer
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients with Non-muscle Invasive Bladder Cancer
Status: Approved
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin